Overall mortality

Mortality from endometrial cancer

 

N

Deaths N

5-year survival
(95% CI)

Unadjusted
HR (95% CI)

P-value

Adjusted HR
(95% CI)a

P-value

Deaths N

5-year survival
(95% CI)

Unadjusted
HR (95% CI)

P-value

Adjusted HR
(95% CI) b

P-value

All patients

None

87

11

87% (80-94)

1c

 

1c

 

5

94% (89-99)

1c

 

1c

 

Brachytherapy

94

8

91% (86-97)

0.7 (0.3-1.7)

.388

1.1 (0.4-2.8)

.892

5

94% (90-99)

0.9 (0.3-3.2)

.899

1.3 (0.4-4.8)

.667

External +/-  Brachytherapy

89

14

84% (76-92)

1.3 (0.6-2.9)

.480

3.2 (1.2-8.7)

.020

9

89% (82-96)

1.9 (0.6-5.6)

.260

3.6 (1.0-13.4)

.059

Low risk (myometrial invasion <50%, grade 1-2)

None

61

6

90% (82-97)

1c

 

1c

 

2

97% (92-100)

1c

 

1c

 

Brachytherapy

75

5

93% (88-99)

0.7 (0.2-2.2)

.426

1.6 (0.4-1.3))

.476

2

97% (93-100)

0.8 (0.1-5.7)

.832

1.7 (0.2-13.9)

.642

External +/-  Brachytherapy

26

4

84% (70-99)

1.7 (0.5-5.9)

.639

6.4 (1.3-30.2)

.020

3

89% (76-100)

3.7 (0.6-22.4)

.149

9.4 (1.0-86.7)

.047

High risk (myometrial invasion <50%, grade 3 or myometrial invasion >=50%, grade 1-2)

None

26

5

80% (65-96)

1c

 

1c

 

3

87% (74-100)

1c

 

1c

 

Brachytherapy

19

3

84% (68-100)

0.8 (0.2-3.5)

.802

1.0 (0.2-4.3)

.973

3

84% (68-100)

1.4 (0.3-6.9)

.682

1.6 (0.3-8.1)

.564

External +/-  Brachytherapy

63

10

90% (74-93)

0.9 (0.3-2.5)

.792

1.7 (0.5-6.3)

.396

6

90% (82-98)

0.9 (0.2-3.5)

.838

1.9 (0.4-9.1)

.453


aAdjusted for age (continuous), tumour risk category and sector of care
bAdjusted for age (continuous) and tumour risk category
cReference category
Table 3: Number of deaths, overall and five-year disease-specific survival and all cause mortality and endometrial cancer mortality risks according to type of radiotherapy for low risk and high risk patients.